APA (7th ed.) Citation

M, R., S, B., O, F., L, I., J, M., MT, B., . . . M, S. (2026). Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study). Targeted oncology. https://doi.org/10.1007/s11523-026-01238-9

Chicago Style (17th ed.) Citation

M, Rizzo, et al. "Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)." Targeted Oncology 2026. https://doi.org/10.1007/s11523-026-01238-9.

MLA (9th ed.) Citation

M, Rizzo, et al. "Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)." Targeted Oncology, 2026, https://doi.org/10.1007/s11523-026-01238-9.